80477-52-7

Usage

Uses

Used in Pharmaceutical Research:
N-Benzyl-1,2,3,6-tetrahydropyridine hydrochloride is used as a research tool for studying the pathophysiology of Parkinson's disease. Its ability to induce parkinsonism in animal models provides insights into the biochemical and physiological processes involved in the condition.
Used in Drug Development:
In the pharmaceutical industry, N-Benzyl-1,2,3,6-tetrahydropyridine hydrochloride is utilized as a compound to test and develop potential treatments for Parkinson's disease. Its role in inducing parkinsonism serves as a model for evaluating the efficacy of new drugs aimed at treating or managing the symptoms of the disease.

InChI:InChI=1/C12H15N.ClH/c1-3-7-12(8-4-1)11-13-9-5-2-6-10-13;/h1-5,7-8H,6,9-11H2;1H

Upstream product

• 100-39-0 benzyl bromide 
• 2589-31-3 N-benzylpyridinium bromide 
• 40240-12-8 1-benzyl-1,2,3,6-tetrahydropyridine 
• 110-86-1 pyridine 

Downstream Products

• 80477-53-8 N⁽¹⁾-benzyl-3,4-dihydroxypiperidine 
• 2905-56-8 N-Benzylpiperidine 
• 80477-54-9 1-benzylpiperidine-cis-diol acetonide 

Relevant academic research and scientific papers

Time-dependent slowly-reversible inhibition of monoamine oxidase A by N-substituted 1,2,3,6-tetrahydropyridines

A novel class of N-substituted tetrahydropyridine derivatives was found to have multiple kinetic mechanisms of monoamine oxidase A inhibition. Eleven structurally similar tetrahydropyridine derivatives were synthesized and evaluated as inhibitors of MAO-A and MAO-B. The most potent MAO-A inhibitor in the series, 2,4-dichlorophenoxypropyl analog 12, displayed time-dependent mixed noncompetitive inhibition. The inhibition was reversed by dialysis, indicating reversible enzyme inhibition. Evidence that the slow-binding inhibition of MAO-A with 12 involves a covalent bond was gained from stabilizing a covalent reversible intermediate product by reduction with sodium borohydride. The reduced enzyme complex was not reversible by dialysis. The results are consistent with slowly reversible, mechanism-based inhibition. Two tetrahydropyridine analogs that selectively inhibited MAO-A were characterized by kinetic mechanisms differing from the kinetic mechanism of 12. As reversible inhibitors of MAO-A, tetrahydropyridine analogs are at low risk of having an adverse effect of tyramine-induced hypertension.